+
OneSource, Xbrane Partner for Global Biosimilar Supply
ECONOMY & POLICY

OneSource, Xbrane Partner for Global Biosimilar Supply

OneSource Specialty Pharma Limited, a multi-modality specialty pharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic manufacturing partnership with Sweden-based Xbrane Biopharma AB (Nasdaq: XBRANE), a leading biotechnology firm. The collaboration will focus on the commercial production of Xbrane’s biosimilar portfolio.

Xbrane’s biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci—a biosimilar of ranibizumab—has already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.

Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource’s state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane’s global supply chain and enhancing the regulatory readiness of OneSource’s biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

As part of the collaboration, OneSource has also taken part in Xbrane’s most recent funding round, underlining the long-term strategic alignment between the two firms.

Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, “The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”

Martin Åmark, CEO of Xbrane Biopharma, added, “Our partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.”

The collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.


OneSource Specialty Pharma Limited, a multi-modality specialty pharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic manufacturing partnership with Sweden-based Xbrane Biopharma AB (Nasdaq: XBRANE), a leading biotechnology firm. The collaboration will focus on the commercial production of Xbrane’s biosimilar portfolio.Xbrane’s biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci—a biosimilar of ranibizumab—has already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource’s state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane’s global supply chain and enhancing the regulatory readiness of OneSource’s biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).As part of the collaboration, OneSource has also taken part in Xbrane’s most recent funding round, underlining the long-term strategic alignment between the two firms.Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, “The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”Martin Åmark, CEO of Xbrane Biopharma, added, “Our partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.”The collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.

Next Story
Real Estate

DLF Returns to Mumbai with Premium Andheri Residential Project

Delhi-NCR based real estate major DLF announced its return to the Mumbai market on 17 July with the launch of its premium residential project, The WestPark, in Andheri. The first phase includes 416 apartments spread across four towers, with two towers launched on the announcement day. The company plans to invest over Rs 8 billion in the project and expects a topline exceeding Rs 20 billion from Phase 1.“We have launched two towers and, given the strong response, plan to unveil the remaining two towers ahead of schedule, within the next few days,” said Aakash Ohri, Joint Managing Director o..

Next Story
Infrastructure Urban

APCRDA Advances Net Zero Goal with IGBC Training for Officials

In a significant stride towards Andhra Pradesh’s Net Zero target by 2040 and the Swarna Andhra 2047 vision, the Andhra Pradesh Capital Region Development Authority (APCRDA), in partnership with the Indian Green Building Council (IGBC), conducted a high-level capacity-building programme for senior officials in Vijayawada on Friday.Held at a city hotel, the session saw the participation of over 50 senior APCRDA officials, including the Engineer-in-Chief, Chief Engineer (H&B), Director (Planning), Director (Environment), and heads of key departments. The training centred on IGBC’s Green B..

Next Story
Infrastructure Energy

Assam Solar Project Halted as Waaree EPC Contract Is Cancelled

Following the Assam government’s withdrawal from its proposed solar project, the Engineering, Procurement, and Construction (EPC) contract awarded to Waaree Renewable has been suspended. Waaree Group’s EPC division informed the stock exchange of this development through a regulatory filing.The Assam solar project was suspended due to funding challenges, which rendered the initiative unviable for the state government. Waaree Renewable Transmission Limited (RTL) explained that the Government of Assam has withdrawn the project’s funding via the Asian Development Bank (ADB) loan. Consequentl..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?